|
ИСТИНА |
Войти в систему Регистрация |
ИСТИНА ЦЭМИ РАН |
||
Neuroprotective proline containing dipeptide Noopept ameliorates NGF and BDNF deficit in pancreas and liver caused by diabetogenic toxin streptozotocine on Wistar ratsстатья
- Авторы: Ostrovskaya R., Antipova T., Ozerova I., Nikolaev S.
- Журнал: Journal of diabetes & metabolism
- Том: 7
- Номер: S7
- Год издания: 2016
- Издательство: OMICS Pub. Group
- Местоположение издательства: Sunnyvale, Calif., United States
- Первая страница: 75
- Последняя страница: 75
- Аннотация: Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) revealed wide spectrum of neuroprotective effects and one of the mechanisms underlying this neuroprotection is the increase of Nerve Growth Factor (NGF) and Brain-derived Neurotrophic Factor (BDNF) expression in hippocampus and hypothalamus. Features of neurons and pancreatic beta-cells similarity as well as insufficient data on neurotrophines on diabetes prompted us to study the effects of Noopept 0.5 mg/kg i.p. for 14 days, before streptocotozine 40 mg/kg i.p. on rats. Irrespective of well-known STZ ability to produce hyperglycemia and weight loss, we revealed pronounced decrease of NGF and BDNF content in pancreatic and hepatic tissues. Noopept was firstly shown to ameliorate hyperglycemia, weight loss as well as to overcome NGF and BDNF deficits in these organs but from the recent study of Vahitova et al. it revealed Noopept ability to increase the content of HIF-1. Involvement of HIF-1 deficiency in pathogenesis of diabetes combined with HIF ability to increase neurotrophines expression allow to consider HIF-positive effects of Noopept as one of the mechanism underlying above-listed anti-diabetic effect of Noopept.
- Добавил в систему: Николаев Сергей Владимирович